Recurrent aseptic meningitis with PIGT mutations: A novel pathogenesis of recurrent meningitis successfully treated by eculizumab

14Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

We report the case of a patient with PIGT mutations who experienced recurrent aseptic meningitis 121 times over 16 years before developing paroxysmal nocturnal haemoglobinuria (PNH). Each episode was preceded by urticaria and arthralgia. After developing PNH, haemolysis occurred prior to meningitis. Flow cytometry revealed deficiency of the glycophosphatidylinositol (GPI)-anchored complement regulatory proteins, CD59 and CD55, and he was diagnosed with PNH. All the symptoms disappeared on administering eculizumab, an anti-C5 antibody. We did not detect mutation in PIGA, which is regarded as the cause of PNH. However, we detected a germ-line mutation and a somatic microdeletion in chromosome 20q including PIGT; PIGT is essential for transferring GPI anchor to the precursors of CD59 and CD55, which play important roles in complement regulation. Loss of these proteins leads to complement overactivation, causing inflammatory symptoms, including recurrent meningitis. PIGT mutations should be considered a novel pathogenesis of recurrent meningitis of unknown aetiology.

Cite

CITATION STYLE

APA

Kawamoto, M., Murakami, Y., Kinoshita, T., & Kohara, N. (2018). Recurrent aseptic meningitis with PIGT mutations: A novel pathogenesis of recurrent meningitis successfully treated by eculizumab. BMJ Case Reports, 2018. https://doi.org/10.1136/bcr-2018-225910

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free